...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Medications for adolescents and young adults with autism spectrum disorders: A systematic review
【24h】

Medications for adolescents and young adults with autism spectrum disorders: A systematic review

机译：青少年自闭症谱系障碍药物：系统评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND OBJECTIVE: Although many treatments have been studied in children with autism spectrum disorders (ASDs), less attention has focused on interventions that may be helpful in adolescents and young adults with ASD. The goal of this study was to systematically review evidence regarding medication treatments for individuals between the ages of 13 and 30 years with ASD. METHODS: The Medline, PsycINFO, and ERIC databases were searched (1980-December 2011), as were reference lists of included articles. Two investigators independently assessed studies against predetermined inclusion/exclusion criteria. Two investigators independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength of evidence ratings on the basis of predetermined criteria. RESULTS: Eight studies of medications were identified that focused on 13- to 30-year-olds with ASD; 4 of the studies were of fair quality. The strength of evidence was insufficient for all outcomes associated with medications tested in this population; however, the 2 available studies of the atypical antipsychotic medication risperidone in this age range were consistent with the moderate evidence in children with ASD for treating problem behavior, including aggression, and high strength of evidence for adverse events, including sedation and weight gain. CONCLUSIONS: There is a marked lack of data on use of medication treatments for adolescents and young adults with ASD. The evidence on the use of risperidone in this age range is insufficient when considered alone but is consistent with the data in the population of children with ASD.
机译：背景与目的：尽管对自闭症谱系障碍（ASD）的儿童进行了许多研究，但较少关注的重点放在可能对青少年和ASD成年人有用的干预上。这项研究的目的是系统地审查有关13岁至30岁的ASD患者的药物治疗的证据。方法：检索Medline，PsycINFO和ERIC数据库（1980年12月至2011年12月），以及所包含文章的参考列表。两名研究者根据预定的纳入/排除标准独立评估了研究。两名研究人员独立提取有关参与者和干预特征，评估技术和结果的数据，并根据预定标准分配证据质量的总体质量和强度。结果：确定了八项针对13至30岁ASD的药物研究。其中有4项研究质量中等。证据强度不足以针对该人群中与药物测试相关的所有结局;但是，有2项针对该年龄段的非典型抗精神病药物利培酮的可用研究与ASD儿童治疗问题行为（包括攻击性）的中度证据一致，并且不良事件（包括镇静和体重增加）的证据也很高。结论：对于ASD的青少年和年轻人，使用药物治疗的数据明显缺乏。单独考虑使用该年龄段使用利培酮的证据不足，但与ASD儿童人群的数据一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号